Johnson & Johnson $JNJ Stock: Courier Capital LLC Cuts Stake

Key Points

• Courier Capital LLC cut its Johnson & Johnson stake by 88.6% in the third quarter, selling 57,138 shares and retaining 7,348 shares worth approximately $1.95 million. Institutional investors still own 69.55% of JNJ.
• Johnson & Johnson reported third-quarter adjusted EPS of $2.59, beating estimates, while revenue rose 5.9% year over year to $25.4 billion. Management also raised its 2026 outlook, although MedTech weakness and litigation-related charges pressured reported results.
• Analysts maintain a generally positive view, with JNJ carrying a “Moderate Buy” consensus rating and a $276.22 average price target. The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.2% annualized yield.

Courier Capital LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 88.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,348 shares of the company's stock after selling 57,138 shares during the quarter. Courier Capital LLC's holdings in Johnson & Johnson were worth $1,945,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. National Pension Service grew its position in shares of Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock valued at $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B lifted its position in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC boosted its stake in Johnson & Johnson by 76.1% during the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock valued at $3,697,000 after purchasing an additional 6,539 shares during the period. Finally, Gradient Investments LLC boosted its stake in Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after purchasing an additional 13,737 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. TD Cowen raised their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a report on Monday, July 13th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Guggenheim restated a "buy" rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Finally, Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $276.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 87,569 shares of company stock valued at $23,064,544. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded down $14.83 on Tuesday, hitting $248.90. 16,613,205 shares of the stock traded hands, compared to its average volume of 7,994,569. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $599.83 billion, a PE ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21. The business has a fifty day moving average price of $266.01 and a two-hundred day moving average price of $249.31.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. The company's revenue for the quarter was up 5.9% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 11.18 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.